Brief Symptom Inventory 18
Overview: Shortened form of the BSI® instrument that provides a highly sensitive assessment of psychological factors.
Qualification Level: B, Q1, Q2
Age Range: Individuals 18 years and older
Administration: Paper-and-pencil, computer or online administration
Completion Time: Approx. 4 minutes (18 items; 5-point rating scale)
Scoring Options: Q-global™ Scoring & Reporting, Q™ Local Software, Manual Scoring, Fax-in Service, or PAD
Publication Date: 2001
The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment.
Psychologists, psychiatrists, physicians, nurses and other health care professionals can use the BSI 18 assessment to help:
- Assess patients at intake for psychological problems
- Measure patient progress during and after treatment to monitor change
- Support managed care decisions
- Provide outcomes measurement for treatment programs
- The BSI 18 test can be completed in approximately 4 minutes. Designed to be brief and easy to administer, the BSI 18 assessment is well-suited for helping measure symptom change throughout treatment.
- The test helps measure three primary symptom dimensions and is designed to provide an overview of a patients symptoms and their intensity at a specific point in time.
- Dimension and global scores form the BSI 18 test correlate highly (i.e., > .90) with analogous score from the SCL-90-R test based on a large community population.
SOM - Somatization
DEP - Depression
ANX - Anxiety
GSI - Global Severity Index, Helps measure overall psychological distress level
Adult community norms
The adult community norms are based on 1,122 individuals—605 males and 517 females.
The oncology norms are based on 1,543 individuals—802 males and 741 females.
Profile Report (Product Number 51947)
Presents raw and normalized T scores for each of the three Primary Symptom Dimensions and the Global Severity Index. The plotted T scores are based on your choice of the community or oncology norms (the T scores for the remaining norm group are printed below the profile).
Progress Report (Product Number 51948)
This report is designed for monitoring a client's progress over time. Provided at no additional charge, it graphically displays scale by scale changes in a client's scores for up to five previously reported BSI 18 administrations.
Q-global™ Web-based Administration, Scoring, and Reporting – Enables you to quickly assess and efficiently organize examinee information, generate scores, and produce accurate comprehensive reports all via the Web.
Q Local™ Software - Enables you to score assessments, report results, and store and export data on your computer.
Manual Scoring - Administer assessments on answer sheets and score them quickly yourself with an answer key.
Fax-in Service - Specially designed answer sheets are faxed to us for processing within 1-2 hours of receipt and returned via fax.
PAD (Patient Assessment Device) Hand-held Electronic Device - Administer the test on a portable, hand-held device. The PAD is placed on a docking station connected to a printer and a results report is printed immediately.
The Derogatis Checklist Series: SCL-90-R, BSI, and BSI 18
Presenter: Leonard Derogatis
Learn about how you can better serve your client’s needs and expand your practice with the use of the Derogatis Checklist Series. Dr. Derogatis, a global authority on symptom checklists and outcomes measurement and author of the SCL-90-R®, BSI®, and BSI 18 tests, will present a free webinar on the history, design, and application of these respected instruments. Quick and easy to administer, the Derogatis Checklist Series is widely used in a variety of settings, including clinical practice, medical settings, and clinical trials.
Date: May 11, 2011